Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Biomarker research is continuously expanding in the field of clinical proteomics. A combination of different proteomic–based methodologies can be applied depending on the specific clinical context of use. Moreover, current advancements in proteomic analytical platforms are leading to an expansion of biomarker candidates that can be identified. Specifically, mass spectrometric techniques could provide highly valuable tools for biomarker research. Ideally, these advances could provide with biomarkers that are clinically applicable for disease diagnosis and/ or prognosis. Unfortunately, in general the biomarker candidates fail to be implemented in clinical decision making. To improve on this current situation, a well‐defined study design has to be established driven by a clear clinical need, while several checkpoints between the different phases of discovery, verification and validation have to be passed in order to increase the probability of establishing valid biomarkers. In this review, we summarize the technical proteomic platforms that are available along the different stages in the biomarker discovery pipeline, exemplified by clinical applications in the field of bladder cancer biomarker research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NCBI GEO: archive for functional genomics data sets—update
Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1193 · Cited by 10,418
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.-H., Pagès, F., Trajanoski, Z., & Galon, J. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp101 · Cited by 6,280
Network medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034 · cited 1×
“[158-164].”
Anderson, N. L., & Anderson, N. G. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r200007-mcp200 · Cited by 4,414
Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation
Merico, D., Isserlin, R., Stueker, O., Emili, A., & Bader, G. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013984 · Cited by 2,235 · cited 2×
“Some of the computational tools for integrating proteomics datasets on a pathway level are: 1) Pathway analysis: KEGG [139], Ingenuity Pathway Analysis (www.ingenuity.com) MetaCore (http://host.genego.com/metacore.php) 2) Pathway mapping: Reactome [140], PathViso [141], BioCyc plugin [142] 3) Gene Ontology analysis: C…”
MethodProtein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867 · cited 2×
“Discovering biomarkers is a multi-parameter process [8-10] and applying them to routine practice needs a proper consideration of multiple issues [11].”
BackgroundProtein Analysis by Shotgun/Bottom-up Proteomics
Zhang, Y., Fonslow, B. R., Shan, B., Baek, M.-C., & Yates, J. R. (2013) · Chemical Reviews · doi:10.1021/cr3003533 · Cited by 1,491
Assigning Significance to Peptides Identified by Tandem Mass Spectrometry Using Decoy Databases
Käll, L., Storey, J. D., MacCoss, M. J., & Noble, W. S. (2008) · Journal of Proteome Research · doi:10.1021/pr700600n · Cited by 607 · cited 1×
“Strategies to evaluate the false discovery rate for mass spectrometry results include searching against concatenated (chimeric database, composed from targeted and decoy database) [83] or decoy database [84], application of statistical models [85,86], or utilization of scoring system [87].”
MethodTabb, D. L., Vega-Montoto, L., Rudnick, P. A., Variyath, A. M., Ham, A.-J. L., Bunk, D. M., Kilpatrick, L. E., Billheimer, D. D., Blackman, R. K., Cardasis, H. L., et al. (2010) · Journal of Proteome Research · doi:10.1021/pr9006365 · Cited by 551
Cited by
Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer
Borrebaeck, C. A. K. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.153 · Cited by 435
Biomarkers in Psychiatry: Concept, Definition, Types and Relevance to the Clinical Reality
García-Gutiérrez, M. S., Navarrete, F., Sala, F., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00432 · Cited by 331
Nakayasu, E. S., Gritsenko, M., Piehowski, P. D., Gao, Y., Orton, D. J., Schepmoes, A. A., Fillmore, T. L., Frohnert, B. I., Rewers, M., Krischer, J. P., et al. (2021) · Nature Protocols · doi:10.1038/s41596-021-00566-6 · Cited by 275
Cilento, E. M., Jin, L., Stewart, T., Shi, M., Sheng, L., & Zhang, J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14635 · Cited by 60
del Campo, M., Jongbloed, W., Twaalfhoven, H. A. M., Veerhuis, R., Blankenstein, M. A., & Teunissen, C. E. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00202 · Cited by 34
“Most of the identified biomarker candidates have not yet been validated, which hampers their implementation in clinical practice (8).”
Background
Metadata
- Authors
- Frantzi, M., Bhat, A., & Latosinska, A.
- Venue
- Clinical and Translational Medicine
- Publisher
- Wiley
- Published
- 2014-03-29
- Volume
- 3
- Issue
- 1
- Pages
- 7-7
- ISSN
- 2001-1326 (ISSN-L)
- OpenAlex
- W2120527469
- Cited by
- 137
- References
- 16
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. https://app.cochat.ai/papers/10.1186/2001-1326-3-7
- The paper
- Frantzi, M., Bhat, A., & Latosinska, A. (2014). Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clinical and Translational Medicine. https://doi.org/10.1186/2001-1326-3-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.